Skip to Content

Invesco Biotechnology & Genome ETF PBE

Medalist Rating as of | See Invesco Investment Hub

Morningstar’s Analysis PBE

Will PBE outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Invesco Biotechnology& Genome ETF earns a Morningstar Medalist Rating of Negative with strength in areas such as People offset by weaker spots such as Process.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a cost advantage over competitors, priced within the least expensive fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings PBE

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 46.6
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Biomarin Pharmaceutical Inc

5.42 12.6 Mil
Healthcare

Neurocrine Biosciences Inc

5.29 12.3 Mil
Healthcare

Regeneron Pharmaceuticals Inc

4.98 11.6 Mil
Healthcare

Bio-Techne Corp

4.95 11.5 Mil
Healthcare

Gilead Sciences Inc

4.93 11.5 Mil
Healthcare

Vertex Pharmaceuticals Inc

4.92 11.4 Mil
Healthcare

Amgen Inc

4.92 11.4 Mil
Healthcare

Biogen Inc

4.71 11.0 Mil
Healthcare

MannKind Corp

3.28 7.6 Mil
Healthcare

Collegium Pharmaceutical Inc

3.17 7.4 Mil
Healthcare